# US 2026/0015587 A1 · Compositions and methods for growing esophageal cells and related uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0015587 A1
- Document ID: US20260015587A1
- Status: Published application
- Kind: A1
- Application number: 18/994,414
- Filed: 2023-08-21
- Published: 2026-01-15
- Earliest claimed: 2022-08-22
- Assignees: The Regents of the University of Michigan
- Applicants: The Regents of the University of Michigan
- Inventors: Jason Spence; Daysha Ferrer-Torres
- Web page: https://patentgrep.com/patent/US20260015587A1

## CPC

- C12N 5/0679: {Cells of the gastro-intestinal tract}
- A61K 35/38: Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
- C12N 2501/11: Epidermal growth factor [EGF]
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2501/39: Steroid hormones
- C12N 2501/415: Wnt; Frizzeled
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2502/13: connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N 2513/00: 3D culture
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Improved techniques for maintaining long-term cultures of the healthy and diseased human esophagus established in 2-dimension (2D) and 3-dimension is also needed. The invention disclosed herein generally relates to methods and systems for culturing and expanding esophageal cells with a growth media comprising a rho-kinase inhibitor, a WNT-activator/agonist, EGF, an inhibitor of TGF-BETA signaling, an inhibitor of BMP signaling, and hydrocortisone.

## Claims

### Claim 1

A method, comprising culturing obtained esophageal cells in vitro, wherein the culturing of the obtained esophageal cells results in expanded esophageal cells, wherein the culturing comprises seeding the obtained esophageal cells with a growth medium comprising hydrocortisone, epidermal growth factor (EGF), a rho-kinase inhibiting agent, a Wnt signaling pathway activating agent, a TGFβ inhibiting agent, and a BMP inhibiting agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein the growth medium comprises hydrocortisone, EGF, Y-276327, CHIR99021, A-8301, and noggin.

### Claim 3 (depends on 1)

The method of claim 1, wherein the expanded esophageal cells are 2-dimensional esophageal cells and/or 3-dimensional esophageal cells.

### Claim 4 (depends on 1)

The method of claim 1, wherein the amount of growth medium utilized in the culturing step is approximately 2 ml within a 9.8 cm2 well, which results in generation of 2-dimensional expanded esophageal cells.

### Claim 5 (depends on 1)

The method of claim 1, wherein the amount of growth medium utilized in the culturing step is approximately 4 ml within a 9.8 cm2 well, which results in generation of 3-dimensional expanded esophageal cells.

### Claim 6 (depends on 1)

The method of claim 1, the obtained esophageal cells are one or more of:
esophageal cells comprised within a biopsy sample from a subject (e.g., a human subject),
esophageal cells comprised within a surgical specimen sample from a subject (e.g., a human subject),
fetal esophageal cells,
adult esophageal cells,
esophageal stem cells, and
differentiated esophageal cells.

### Claim 7 (depends on 1)

The method of claim 1, wherein the obtained esophageal cells are fetal esophageal cells.

### Claim 8 (depends on 1)

The method of claim 1, wherein the obtained esophageal cells are adult esophageal cells.

### Claim 9 (depends on 1)

The method of claim 1, wherein prior to the culturing step the esophageal cells are minced or enzymatically digested.

### Claim 10 (depends on 1)

The method of claim 1, wherein the expanded esophageal cells possess esophageal stem cells and/or differentiated esophageal cells.

### Claim 11 (depends on 1)

The method of claim 1, wherein the expanded esophageal cells are capable of being cryopreserved.

### Claim 12 (depends on 11)

The method of claim 11, wherein the cryopreserved expanded esophageal cells can be thawed for purposes of generation of esophageal cell lines (e.g., 2-dimensional).

### Claim 13 (depends on 11)

The method of claim 11, wherein the cryopreserved expanded esophageal cells can be thawed for purposes of generation of esophageal organoid tissue (e.g., 3-dimensional).

### Claim 14 (depends on 1)

The method of claim 1, wherein the expanded esophageal cells are stratified esophageal epithelium cells.

### Claim 15 (depends on 1)

The method of claim 1, wherein the expanded esophageal cells comprise 2-dimensional stratified esophageal epithelium.

### Claim 16 (depends on 1)

The method of claim 1, wherein the expanded esophageal cells comprise 3-dimensional stratified esophageal epithelium (e.g., 3-dimensional esophageal organoid tissue).

### Claim 17 (depends on 1)

The method of claim 1, wherein the culturing further comprises seeding the esophageal cells onto sub-lethally irradiated feeder cells and the growth media.

### Claim 18 (depends on 17)

The method of claim 17, wherein the sub-lethally irradiated feeder cells are 3T3-J2i sub-lethally irradiated feeder cells.

### Claim 19 (depends on 1)

The method of claim 1, wherein the culturing further comprises seeding the esophageal cells onto solubilized basement membrane matrix cells and the growth media.

### Claim 20 (depends on 19)

The method of claim 19, wherein the solubilized basement membrane matrix cells are matrigel cells.

### Claim 21 (depends on 1)

A composition comprising or consisting of expanded esophageal cells produced in vitro from the method of claim 1.

### Claim 22 (depends on 1)

A kit comprising or consisting of expanded esophageal cells produced in vitro from the method of claim 1.
